DOCSLIB.ORG

Oncomed Gets Its Groove Back with Big Celgene Deal

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Oncomed Gets Its Groove Back with Big Celgene Deal December 04, 2013 OncoMed gets its groove back with big Celgene deal Jonathan Gardner Until its $177m partnership with Celgene, announced yesterday, OncoMed Pharmaceuticals was not benefiting from a float on the public markets in the midst of a biotech bubble. Shares had sunk below the price paid by the favoured investors who bought at the IPO value of $17. Fortunately, signing a multi-agent deal re-energised shares in the California-based group; they nearly doubled to $27.70. Buoyant executives told analysts the lavishness of the deal should provide sufficient funding to support development of the entire pipeline: “We may not have to raise cash again, ever,” chief executive Paul Hastings said on a conference call. A different target Celgene snared options to up to six candidates being developed by OncoMed that target pathways used by cancer stem cells, also known as tumour-initiating cells. As with non-malignant stem cells, these have the ability to self-renew and differentiate, and are believed to play a role in growth, recurrence, metastasis and resistance. They were first discovered in leukaemia, and are now known to exist in solid tumours too. OncoMed’s lead candidate is demcizumab, currently in a phase I/II trial in combination with paclitaxel in platinum-resistant ovarian cancer. The group is also shooting for the moon, with phase I trials under way with standard of care chemotherapies in advanced pancreatic cancer and non-small cell lung cancer. The antibody blocks the anti-delta-like 4 (DLL4) ligand, which is important to the notch signalling pathway involved in cell proliferation. The deal brings in $155m in cash up front and an additional $22.3m equity investment, with Celgene now a 5% shareholder after buying close to 1.5 million shares at $15.13. For four of the six programmes, OncoMed will pay for all development costs through execution of options, after which Celgene will pay for two thirds of development costs. OncoMed can opt in to fifty-fifty co-commercialisation and profit-sharing rights in the US. Two other programmes, an undisclosed biological and an undisclosed small-molecule target, are subject to global licensing agreements. With the deal, Mr Hastings said OncoMed now had pro-forma cash of $322m, and milestone payments could begin flowing in as soon as next year. “This will allow us to underwrite our phase II programme, expand the phase I programme for additional indications and increase our shots on goal,” he told analysts in a conference call. Shares continued to rise today, standing at $31.15, a 12% rise, in mid-morning trading. Seasoned player OncoMed was not exactly in need of big pharma validation of its approach, as it had already signed preclinical deals with both Bayer and GlaxoSmithKline (Bayer takes early stage gamble on OncoMed’s cancer stem cell treatment, June 17, 2010). However, the size of the Celgene collaboration is the clearest sign that there could be greater interest in this space. But the share performance since the market flotation is more curious: the stock sank to less than $20 about six weeks after the IPO and spent all of November below $15. Planning to undertake 11 clinical trials by the end of 2013, when $128m in cash was available at September 30, could have made some investors nervous about the group’s ability to execute such a broad strategy. The influx of cash from Celgene should put any such fears to rest. Meanwhile, Celgene has a number of reliable money-makers on the market in oncology in Revlimid and Abraxane, and has just launched Pomalyst, but aside from potential launch of the psoriatic arthritis drug Apremilast it has few pipeline catalysts approaching. Putting its cash to good use probably precludes most acquisitions at current valuations – a broad deal in an innovative space like cancer stem cells is a sensible alternative. To contact the writer of this story email Jonathan Gardner in London at [email protected] or follow @JonEPVantage on Twitter More from Evaluate Vantage Evaluate HQ 44-(0)20-7377-0800 Evaluate Americas +1-617-573-9450 Evaluate APAC +81-(0)80-1164-4754 © Copyright 2021 Evaluate Ltd..
Load more

Recommended publications
  • 2019 Breakthrough Summit Co-Host Committee 2019 Breakthrough
    2019 Breakthrough Summit Co-Host Committee All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution Stock and Other Patents, Royalties, Travel, Speakers' Expert Name Employment Leadership Ownership Honoraria Consulting or Advisory Role Research Funding Other Intellectual Accommodations, Other Bureau Testimony Interests Property Expenses Dae Ho Lee Abbvie, AstraZeneca/MedImmune, Boehringer ST Cube Ingelheim, Bristol-Myers Squibb, Chong Kun Dang Pharmaceutical, CJ Healthcare, Janssen, Lilly, Merck, MSD, Mundipharma, Novartis, Ono Pharmaceutical, Pfizer, Roche/Genentech, Samyang, ST Cube, Takeda Ekaphop Amgen, AstraZeneca, Boehringer Ingelheim, Bristol- AstraZeneca, MSD, Sirachainan Myers Squibb, Diethelm Keller Logistics, LF Asia, Pfizer Merck, MSD, Mundipharma, Roche, Sanofi/Aventis Lillian L. Siu Agios (I) Agios (I) AstraZeneca/MedImmune, Loxo, Merck, Amgen (Inst), Astellas Pharma (Inst), AstraZeneca (Inst), Bayer (Inst), MorphoSys, Roche, Symphony Evolution Boehringer Ingelheim (Inst), Bristol-Myers Squibb (Inst), Genentech/Roche (Inst), GlaxoSmithKline (Inst), MedImmune (Inst), Merck (Inst), Novartis (Inst), Pfizer (Inst), Symphony Evolution (Inst) Virote Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Amgen, AstraZeneca, Boehringer Ingelheim, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Lilly, Amgen, AstraZeneca, Sriuranpong Bristol-Myers Squibb, Eisai, Lilly, MSD Oncology, Eisai, MSD Oncology, Novartis, Roche MSD Oncology,
    [Show full text]
  • Next Generation Immuno-Oncology Targeting Hot and Cold Tumors
    Next generation immuno-oncology targeting hot and cold tumors March 2017 iTeos – General Disclaimer Company Presentation “This presentation has been prepared by iTeos and is furnished to you by iTeos on a confidential basis and solely for your information. This presentation contains forward-looking statements, including (without limitation) statements concerning the progress and expectations of our (pre-)clinical pipeline and the financials of the company. When used in this presentation, the words “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is designed to,” “may,” “might,” “will,” “plan,” “potential,” “possible,” “predict,” “objective,” “should,” and similar expressions are intended to identify forward- looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of iTeos, or industry results, to be materially different from any future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. All statements contained herein speak only as of the release date of this document. iTeos expressly disclaims any obligation to update any statement in this document to reflect any change or future development with respect thereto, any future results, or any change in events, conditions and/or circumstances on which any such statement is based, unless specifically required by law or regulation. Neither iTeos nor any of its officers,
    [Show full text]
  • IGNYTE-ESO: a Master Protocol to Assess Safety and Activity of Letetresgene Autoleucel (Lete-Cel; GSK3377794) Victoria L
    Sandra P. D’Angelo1, Jonathan Noujaim2, Fiona Thistlethwaite3, Albiruni R. Abdul Razak4, Silvia Stacchiotti5, Warren Chow6, John B.A.G. Haanen7, Anna Chalmers8, Steven I. Robinson9, Brian A. Van Tine10, Kristen N. Ganjoo11, Melissa L. Johnson12, 13 13 13 13 13 14 15 IGNYTE-ESO: a master protocol to assess safety and activity of letetresgene autoleucel (lete-cel; GSK3377794) Victoria L. Chiou , Thomas Faitg , Mary Woessner , Laura Pearce , Aiman Shalabi , Jean-Yves Blay , George D. Demetri 1Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Institut D’Hématologie-Oncologie, Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada; 3The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom; 4Princess Margaret Cancer Centre and in HLA-A*02+ patients with synovial sarcoma or myxoid/round cell liposarcoma (Substudies 1 and 2) Mount Sinai Hospital, Toronto, ON, Canada; 5Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 6City of Hope Comprehensive Cancer Center, Duarte, CA, United States; 7Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands; 8Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; 9Mayo Clinic, Rochester, MN, USA; 10Washington University in St. Louis, St. Louis, MO, USA; 11Stanford University Medical Center, Stanford, CA, USA; 12Sarah Cannon Research Institute, Nashville, TN, USA; 13GlaxoSmithKline, Philadelphia, PA, USA; Poster No. TPS11582 14Centre Léon Bérard, Lyon, France; 15Dana-Farber Cancer Institute and Ludwig Center at Harvard, Boston, MA, USA Background Study design Study phases Unmet need IGNYTE-ESO (NCT03967223) is a master protocol that enables evaluation of multiple cell therapies Figure 3 displays the patient journey for both substudies, which includes leukapheresis for lete-cel manufacture, lymphodepletion chemotherapy, lete-cel infusion, and follow-up.
    [Show full text]
  • Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer
    Author Manuscript Published OnlineFirst on December 1, 2017; DOI: 10.1158/2159-8290.CD-17-1009 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Genomic landscape of cell-free DNA in patients with colorectal cancer John H. Strickler1, Jonathan M. Loree2, Leanne G. Ahronian3, Aparna R. Parikh3, Donna Niedzwiecki1, Allan Andresson Lima Pereira2, Matthew Mckinney1, W. Michael Korn4,5, Chloe E. Atreya4, Kimberly C. Banks6, Rebecca J. Nagy6, Funda Meric-Bernstam2, Richard B. Lanman6, AmirAli Talasaz6, Igor F. Tsigelny7,8, Ryan B. Corcoran3 #, Scott Kopetz2 # 1Duke University Medical Center, Durham, NC, USA; 2University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA, USA; 4Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA; Caris Life Sciences, Phoenix, AZ, USA; 6Guardant Health, Inc., Redwood City, CA, USA; 7University of California San Diego, San Diego, CA, USA; 8CureMatch Inc., San Diego, CA, USA. #To whom correspondence should be addressed: Dr. Ryan B. Corcoran Massachusetts General Hospital Cancer Center, 149 13th St., 7th floor Boston, MA 02129 Phone: 617-726-8599 Fax: 617-724-9648 Email: [email protected] Dr. Scott Kopetz University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 426 Houston, TX 77030 Phone: 713-792-2828 Fax: 713-563-2957 Email: [email protected] 1 Downloaded from cancerdiscovery.aacrjournals.org on September 28, 2021. © 2017 American Association for Cancer Research. Author Manuscript Published OnlineFirst on December 1, 2017; DOI: 10.1158/2159-8290.CD-17-1009 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
    [Show full text]
  • Feasibility and First Reports of the MATCH-R Repeated Biopsy Trial At
    www.nature.com/npjprecisiononcology ARTICLE OPEN Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy Gonzalo Recondo 1, Linda Mahjoubi2, Aline Maillard3, Yohann Loriot1,4, Ludovic Bigot1, Francesco Facchinetti1, Rastislav Bahleda2, Anas Gazzah2, Antoine Hollebecque2, Laura Mezquita4, David Planchard1,4, Charles Naltet4, Pernelle Lavaud4, Ludovic Lacroix1,5,6, Catherine Richon5, Aurelie Abou Lovergne7, Thierry De Baere8, Lambros Tselikas8, Olivier Deas9, Claudio Nicotra2, Maud Ngo-Camus2, Rosa L. Frias1, Eric Solary10, Eric Angevin2, Alexander Eggermont4, Ken A. Olaussen1, Gilles Vassal7, Stefan Michiels 3, ✉ Fabrice Andre 1,4, Jean-Yves Scoazec5,6, Christophe Massard1,2, Jean-Charles Soria1,4, Benjamin Besse1,4 and Luc Friboulet 1 Unravelling the biological processes driving tumour resistance is necessary to support the development of innovative treatment strategies. We report the design and feasibility of the MATCH-R prospective trial led by Gustave Roussy with the primary objective of characterizing the molecular mechanisms of resistance to cancer treatments. The primary clinical endpoints consist of analyzing the type and frequency of molecular alterations in resistant tumours and compare these to samples prior to treatment. Patients experiencing disease progression after an initial partial response or stable disease for at least 24 weeks underwent a tumour biopsy guided by CT or ultrasound. Molecular profiling of tumours was performed using whole exome sequencing, RNA sequencing and panel sequencing. At data cut-off for feasibility analysis, out of 333 inclusions, tumour biopsies were obtained in 303 cases (91%). From these biopsies, 278 (83%) had sufficient quality for analysis by high-throughput next generation sequencing (NGS). All 278 samples underwent targeted NGS, 215 (70.9%) RNA sequencing and 222 (73.2%) whole 1234567890():,; exome sequencing.
    [Show full text]
  • Compugen Ltd. (Exact Name of Registrant As Specified in Its Charter and Translation of Registrant's Name Into English) ______
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF EVENT REQUIRING THIS SHELL COMPANY REPORT __________ COMMISSION FILE NO. 000-30902 ____________________________________________________ Compugen Ltd. (Exact name of registrant as specified in its charter and translation of registrant's name into English) ___________________________________________________________________ Israel (Jurisdiction of incorporation or organization) Azrieli Center, 26 Harokmim Street, Building D, Holon 5885849 Israel (Address of principal executive offices) ________________________________________________ Ari Krashin, Chief Financial Officer Phone: +972-3-765-8585, Fax: +972-3-765-8555 Azrieli Center, 26 Harokmim Street, Building D, Holon 5885849 Israel (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) ________________________________________________ Securities registered or to be registered pursuant to Section 12(b) of the Act: Title of each class Name of each exchange on which registered Ordinary shares, par value NIS 0.01 per share The NASDAQ Stock Market LLC (The NASDAQ Global Market) Securities registered or to be registered pursuant to Section 12(g) of the Act: None (Title of Class) Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None Indicate the number of outstanding shares of each of the issuer's classes of capital or common stock as of the close of the period covered by the annual report: 51,293,070 Ordinary Shares Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]
  • Steady Course Or Changing Tides? 2015 Trial Starts 2016 Clinical Trials Roundup – Steady Course Or Changing Tides?
    2016 Clinical Trials Roundup Steady course or changing tides? 2015 Trial Starts 2016 Clinical Trials Roundup – Steady course or changing tides? Welcome to this year’s roundup where we’ll review clinical trials that initiated in 2015 to elucidate any ongoing, or new, trends within the world of pharma R&D. Here we’ll provide a high-level overview of trial activity, focused on the six major therapeutic areas (TAs) of autoimmune/inflammation, cardiovascular, CNS, infectious disease, metabolic/endocrinology, and oncology, with metrics by TA, trial phase, and disease. We’ll then zoom in on the most active industry sponsors, including a closer look at how they may (or may not be) maximizing their assets. Now, let’s take a look at the new clinical research from 2015, and see how the course of pharma R&D fared. Doro Shin, MPH Principal Analyst, Infectious & Genitourinary Diseases Manager, Thought Leadership Program 2 April 2016 © Informa UK Ltd 2016 (Unauthorized photocopying prohibited.) Rounding up the 2015 debuts Similar to years past, this annual roundup will hone in on unapproved drug3 clinical research, which comprised Approximately 4,900 Phase I-III trials started in 2015 2,769 of trials starting in 2015 (57%). Involvement across the six TAs.1 Industry sponsors2 were involved from the industry is increased as 77% of trials initiated in the majority of these trials (2934 of 4895 trials, in 2015 with an unapproved drug is linked to an 60%), particularly in autoimmune research (487 of industry sponsor (2143 of 2769 trials). Again, 668 trials, 73%). Oncology had the lowest rate and autoimmune has the largest industry participation (383 just over half of cancer trials included an industry of 424 trials, 90%) while oncology has the lowest (750 sponsor (1110 of 2080 trials).
    [Show full text]
  • Understanding Life Science Partnership Structures
    MARCH 2009 MEMBER BRIEFING LIFE SCIENCES PRACTICE GROUP Understanding Life Science Partnership Structures Krist Werling, Esquire Bart Walker, Esquire Jessica Smith, Esquire McGuireWoods LLP Chicago, IL, and Charlotte, NC Companies in every industry that have attempted to raise capital and make research and development (R&D) investments over the past twelve months have faced significant challenges. The pharmaceutical and biotechnology sectors are no exception. The Dow Jones U.S. Biotechnology Index was down 18% during 2008, the pharmaceutical index DRG.X lost 19% of its market value. The entire healthcare industry has been battered during this downturn; the medical supply index DJUSAM was down 35% in 2008; managed care companies are down nearly 60%.1 While a significant wave of consolidation is coming (as evidenced by Pfizer’s announced acquisition of Wyeth), the partnership options described in this article offer options for pharmaceutical and device companies in these challenging economic times. Dramatic declines in the capital markets have been in part caused by, and accompanied by the credit crunch. This restriction in available capital has brought significant challenges to transactions in all industries, including healthcare and biotechnology. The Biotechnology Industry Organization, a prominent trade group, recently stated that 180 publicly traded biotech companies have less than one year of cash on hand.2 Both venture capital firms and private equity funds have been unable to structure leveraged buyouts and 1 Lawrence C. Strauss, Health-Care Stocks for an Ailing Economy, BARRON’S, Nov. 24, 2008. 2 Ron Winslow, Investor Prospects Look Grim, WALL ST. J., Jan. 11, 2009. 1 combination transactions requiring significant amounts of debt.
    [Show full text]
  • 2019 Best of ASCO Planning Committee All Relationships Are Considered Compensated
    2019 Best of ASCO Planning Committee All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution Name Employment Leadership Stock and Other Honoraria Consulting or Advisory Role Speakers' Research Funding Patents, Royalties, Other Expert Travel, Accommodations, Other Ownership Bureau Intellectual Property Testimony Expenses Relationship Interests Monica M. Bertagnolli Leap Syntalogic, Syntimmune Abbvie (Inst), Agenus (Inst), Astellas Pharma (Inst), AstraZeneca (Inst), Baxalta (Inst), Therapeutics Bayer Health (Inst), Breast Cancer Research Foundation (Inst), Bristol-Myers Squibb (Inst), Celgene (Inst), Complion (Inst), Eisai (Inst), Exelixis (Inst), Genentech (Inst), GHI Pharma (Inst), Gilead Sciences (Inst), GlaxoSmithKline (Inst), Incyte (Inst), Janssen (Inst), Jazz Pharmaceuticals (Inst), Leidos (Inst), Lexicon (Inst), Lilly (Inst), Matrex (Inst), Mayo Clinic (Inst), Merck (Inst), MGH (Inst), Millenium Pharamceuticals (Inst), Novartis (Inst), Patient Centered Outcomes Research Institute (PCORI) (Inst), Pfizer (Inst), Pharmacyclics (Inst), Robert Wood Johnson Foundation (Inst), Sagerock Advisors (Inst), Sanofi (Inst), Taiho Pharmaceutical (Inst), Takeda (Inst), Tesaro (Inst), Teva (Inst) Melissa L. Johnson Araxes Pharma (Inst), Astellas Pharma (I), Abbvie (Inst), Acerta Pharma (Inst), Adaptimmune (Inst), Amgen (Inst), Array BioPharma Abbvie, Astellas Pharma, AstraZeneca (Inst), BeiGene (Inst), (Inst), AstraZeneca (Inst), BeiGene (Inst), BerGenBio
    [Show full text]
  • Annual Report 2017
    Annual Report 2 017 Augmented Version Bayer Annual Report 2017 The integrated Bayer Annual Report 2017 is available in a print version and in an aug- mented online version (Annual Report 2017 – Augmented Version). The online version contains the notes to the consolidated financial state- ments of the Bayer Group, along with additional information on the management report. The Annual Report 2017 – Augmented Version can be found at www.bayer.com/AR17. Cover photo: Farmer Aaron Gingerich with his daughter Kylie on one of his cornfields in Illinois, United States. You can read more in the Magazine section, which starts on page 8. At a Glance Sales EBITDA Net Income Before Special Items 1 2 +1.5% -0.3 % + 61.9% 2016 2017 Core Earnings per Share Supplier Management Investment in Research and Development 2 +1.0 % 99.5% of all strategically important suppliers billion evaluated since 2012 €4.5 Proportion of Women Specific Greenhouse Gas Emissions3 Energy Efficiency3 in Senior Management 2 - % up by 4.5 2 % 3.8% 32 1 Currency- and portfolio-adjusted 2 Changes from 2016; 2016 figures restated 3 Bayer excluding Currenta Fiscal 2017 Bayer: business at prior-year levelFiscal 2017 – on track with strategy Bayer:Group sales business €35.0 billion (Fx at & portfolioprior-year adj. + 1.5%) levelAnother – recordon trackyear for Pharmaceuticals with strategy Weak business development at Consumer Health CrGropoup Science sales €35.0 business billion down (Fx &against portfolio prior adj. year + 1.5%) due to situation in Brazil – measures taking effect Another
    [Show full text]
  • 13Th Annual Oncology Grand Rounds
    13th Annual Oncology Grand Rounds A Complimentary NCPD Live Webinar Series Held During the 46th Annual ONS Congress Colorectal and Gastroesophageal Cancers Wednesday, April 21, 2021 4:45 PM – 5:45 PM ET Medical Oncologists Oncology Nurse Practitioner Johanna Bendell, MD Jessica Mitchell, APRN, CNP, MPH Daniel Catenacci, MD Moderator Neil Love, MD Medical Oncologists Oncology Nurse Practitioner Johanna Bendell, MD Jessica Mitchell, APRN, CNP, MPH Chief Development Officer Assistant Professor of Oncology Director, Drug Development Unit Nashville Mayo Clinic College of Medicine Sarah Cannon Research Institute and Science Tennessee Oncology Rochester, Minnesota Nashville, Tennessee Daniel Catenacci, MD Associate Professor, Department of Medicine Section of Hematology and Oncology Director, Interdisciplinary Gastrointestinal Oncology Program Assistant Director, Translational Research Comprehensive Cancer Center The University of Chicago Medical Center and Biological Sciences Chicago, Illinois Commercial Support This activity is supported by educational grants from Lilly and Taiho Oncology Inc. Dr Love — Disclosures Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals,
    [Show full text]
  • 2021 Quality Care Symposium Planning Committee All Relationships Are Considered Compensated
    2021 Quality Care Symposium Planning Committee All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution Name Employment Leadership Stock and Other Honoraria Consulting or Advisory Speakers' Bureau Research Funding Patents, Royalties, Other Expert Testimony Travel, Accommodations, Other Relationship (OPTIONAL) (OPTIONAL) Open Ownership Interests Role Intellectual Property Expenses Uncompensated Payments Link Relationships Kerin B. Adelson Emilio Health- Emilio Health- Carrum Health, Emilio Genentech Celgene, HERON, Roche Genentech/Roche Genentech Celgene, Genentech, Genentech/Roche Brightline Health (I) Brightline Health (I) Health-Brightline Health (I), DIS HERON, Roche DIS Lyra Health (I), MindNest Heath (I) Neeraj K. Arora Fumiko Chino Varian (Inst) Janet De Moor Biogen (I) Biogen (I) Biogen (I) John T. Hamm BrightPath AstraZeneca, Meda Abbvie (Inst), Amgen (Inst), ARMO BioSciences (Inst), Astellas Biotheraputics, Exelixis, Pharmaceuticals, Pfizer Pharma (Inst), AstraZeneca (Inst), Boehringer Ingelheim (Inst), Puma Biotechnology Boston Biomedical (Inst), BrightPath Biotheraputics (Inst), Bristol- Myers Squibb (Inst), Cancer Research and Biostatistics (Inst), Celgene (Inst), Clovis Oncology (Inst), Daiichi Sankyo (Inst), Dana Farber Cancer Institute (Inst), Deciphera (Inst), EMD Serono (Inst), EpicentRx (Inst), Exact Sciences (Inst), Five Prime Therapeutics (Inst), G1 Therapeutics (Inst), GBG Forschungs (Inst), Genentech (Inst), Gilead Sciences
    [Show full text]